The field of DMTs is rapidly evolving, with ongoing research and clinical trials aiming to enhance their efficacy and overcome existing challenges. Advances in genomics, biomarker discovery, and artificial intelligence are expected to play a crucial role in the development of next-generation DMTs. Furthermore, combination therapies that integrate multiple DMTs or combine them with traditional treatments are showing promise in improving outcomes for cancer patients.
